4DMedical to Acquire Imbio for ~$45M
Shots:
- The company announces the acquisition of Imbio and strengthens its diagnostic offerings by incorporating Imbio's leading AI solutions
- As per the deal, Imbio is eligible to receive $25M up front along with contingent earnout that includes a tranche of up to $10M in CY2024 & two tranches of up to $5M each in CY2025. The acquisition aligns with 4DMedical's growth plan, introducing 4 new lung diagnostic tools for a comprehensive approach to assessing lung disease
- Moreover, Imbio's acquisition speeds up 4Dmedical's XV Technology commercialization in the US, creating opportunities for patient screening programs targeting COPD, ILD, lung cancer, and heart disease in Australia and the US
Ref: 4DMedical | Image: Imbio
Related News:- Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
